Organization (Hospital)
HOSPICES CIVILS DE LYON
ClinicalTrials.gov lists HOSPICES CIVILS DE LYON as lead sponsor of 1,852 trials. It has 558 active development programs and 103 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 108 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 120 in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 3 trials are registered to start in 2027 or later.
This page covers HOSPICES CIVILS DE LYON: 1,852 lead-sponsored trials and 3 legal-entity registrations. The parent company on record for HOSPICES CIVILS DE LYON is REPUBLIQUE FRANCAISE PRESIDENCE, which does not have its own page on this site.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (763)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 48 |
| Stroke | 45 |
| Diabetes Mellitus | 39 |
| Epilepsy | 38 |
| Obesity | 38 |
Showing 5 of 763 disease areas.
Trials by start year as sponsor or collaborator (31)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 108 |
| 2025 | 112 |
| 2024 | 139 |
| 2023 | 119 |
| 2022 | 126 |
| 2021 | 142 |
| 2020 | 169 |
| 2019 | 152 |
| 2018 | 144 |
| 2017 | 122 |
Showing 10 of 31 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 150 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 1,087 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (558)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PSA dosage | Prostatic Neoplasms | Phase 3 | 2 |
| MRI | Prostatic Neoplasms | Phase 3 | 2 |
| Radiotherapy and PCV chemotherapy | Glioma | Phase 3 | 1 |
| Radiotherapy and PCV chemotherapy | Oligodendroglioma | Phase 3 | 1 |
| Interferon Gamma | Cross Infection | Phase 3 | 1 |
Showing 5 of 558 active programs.
Approved assets (103)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Blood Sampling | 35 |
| BLOOD SAMPLE | 34 |
| Blood Test | 12 |
| BEVACIZUMAB | 6 |
| EVEROLIMUS | 4 |
Showing 5 of 103 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 42% hit target (n=619) | 43% on time (n=609) |
Journals published in (534)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 27 |
| Trials | 25 |
| The New England journal of medicine | 17 |
| Critical care (London, England) | 13 |
| The Cochrane database of systematic reviews | 13 |
Showing 5 of 534 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 48 | 16 | 2025-12-30 |
Organization relationships (323)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Assistance Publique – Hôpitaux de Paris | Co sponsors trial with | 34 |
| University Hospital, Bordeaux | Co sponsors trial with | 15 |
| University Hospital, Grenoble | Co sponsors trial with | 14 |
| University Hospital, Clermont-Ferrand | Co sponsors trial with | 13 |
| Centre Hospitalier Universitaire de Nice | Co sponsors trial with | 13 |
Showing 5 of 323 relationships.
Latest dated events (2,097)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 2,097 events.
Biomarker capability evidence (1,409)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCA4 | Trial sponsor | Named in trial inclusion criteria |
| ABCD1 | Trial sponsor | Named in trial inclusion criteria |
| ABCD1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
Showing 5 of 1,409 evidence rows.
Biomarkers this organization publishes on (770)
Shown in this order: most publications first.
Showing 5 of 770 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.